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Letter to the Editor
tion, and collateral ventilation still need to be defined to fully op-
timize and facilitate patient selection. Furthermore, choosing the 
proper lobar target to collapse is key in the success of endobron-
chial valve therapy, but might be challenging. Lung volume reduc-
tion in emphysema is always balancing between reducing hyper-
inflation and still maintaining sufficient gas exchange. Combining 
imaging techniques such as in- and expiratory HRCT scans and 
lung perfusion scans and further development of quantitative 
HRCT software analysis with accurate assessment of fissure integ-
rity, emphysema scores, the amount of air trapping, and vascular 
volume (Fig. 1), all on a lobar level will increase the knowledge on 
the “best” lobe to treat and result in more insight to predict patients 
who are at risk of a pneumothorax after treatment, which is the 
most common risk.
In all GOLD treatment guidelines, pulmonary rehabilitation is 
an important part of integrated patient management [1]. Most 
clinical trials investigating the endobronchial valve treatment in-
cluded only patients who followed regular maintenance physical 
therapy. However, the combination of endobronchial valve treat-
ment and an actual pulmonary rehabilitation program has never 
been investigated so far. Combining both treatments could 
strengthen the effect of the endobronchial valve treatment, espe-
cially when the patients’ most limiting factor, hyperinflation, has 
been significantly reduced. Hypothetically, the best timing of the 
pulmonary rehabilitation program would be after the endobron-
chial valve treatment instead of before as in current practice. Fol-
lowing, a pulmonary rehabilitation program before and after the 
endobronchial valve treatment could be even better, but probably 
not feasible due to high costs. 
Furthermore, the endobronchial valve treatment achieved re-
duction in hyperinflation. The induced improved ventilatory and 
exercise capacity might cause a lot of metabolic and systemic 
changes, like cardiac function [6], hypothetically reversing the 
long-term downward spiral in emphysema patients at multiple or-
gan system levels [7]. This gives us the chance to learn a lot about 
emphysema pathophysiology in the fields of metabolism, body 
composition, systemic inflammation, muscle function and struc-
ture, cardiac function, and psychological factors.
To date, results have been published on safety and efficacy of 
the endobronchial valve treatment up to 1 year after treatment [8]. 
Currently, about 3 out of 4 treated patients retain the valves 1 year 
later. However, not much is known about the sustainability of the 
valves in the longer term, how many re-bronchoscopies are neces-
sary to achieve this, and how longer-term data on efficacy and ad-
verse events will look. All this is important for further development 
of this treatment, but also to make a rational choice to actually be 
treated.
The Dutch SOLVE consortium (funded by the Dutch Lung 
Foundation) aims to gain knowledge on all these important addi-
tional questions around this innovative BLVR treatment. In this 
consortium, which was formed in 2017, COPD expertise is com-
In 2017, the GOLD-COPD guidelines included for the first 
time the bronchoscopic lung volume reduction (BLVR) treatment 
using one-way endobronchial valves for selected patients with em-
physema [1]. This treatment is a therapeutic, minor invasive bron-
choscopic strategy for patients with severe lung hyperinflation due 
to emphysema, who suffer from severe dyspnea despite optimal 
current available treatment. This treatment has shown to success-
fully improve pulmonary function, exercise capacity, physical ac-
tivity, and quality of life [2–5]. All clinical trials performed to date 
have shown consistent and clinical important outcomes, but have 
also shown the future challenges of the endobronchial valve treat-
ment. 
This point was also highlighted by the GOLD-COPD 2017 re-
port concluding that “additional data are needed to define the op-
timal patient population to receive the treatment and to define the 
long-term durability of improvements” [1]. So there is need for 
additional research to further optimize this promising treatment, 
with key issues being advanced patient selection, positioning of 
pulmonary rehabilitation relative to this treatment, target lobe se-
lection, managing adverse events, and long-term follow-up.
For optimal patient selection, i.e., selection of patients with a 
high likelihood to respond to treatment, it is known that patients 
need to have emphysema with severe hyperinflation and absence 
of collateral ventilation from an adjacent lobe to the target lobe for 
treatment. However, the exact amount of emphysema, hyperinfla-
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bined with the world’s leading experts on pulmonary rehabilita-
tion, body composition, interventional bronchoscopy, and quan-
titative imaging. The research that will be performed over the next 
5 years will lead to important answers about patient selection, 
treatment optimization, exact positioning of pulmonary rehabili-
tation around BLVR, impact on (long-term) efficacy outcomes, 
and emphysema pathophysiology and hopefully will further de-
velop and optimize this innovative and personalized treatment for 
this patient group, who have limited treatment options left (see 
online supplement for the SOLVE study protocol – NCT 03474471; 
www.karger.com/doi/10.1159/000491675).
Take-Home Message
The BLVR treatment using one-way endobronchial valves has 
been shown to successfully improve clinical outcomes but also has 
some future challenges.
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a b
Fig. 1. Example of development of quantitative HRCT software analysis (Thirona, Nijmegen, The Netherlands). 
a Rendering image of lobar volumes which is used for emphysema scores and air trapping and fissure analysis. 
b Rendering image of the bronchial tree (right lung) used for airway dimension analysis and pulmonary vascu-
lature, used for vascular volume and lung perfusion.
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